Last Updated: May 26, 2026

Patent: 8,623,817

✉ Email this page to a colleague

Summary for Patent: 8,623,817

Title:	Method of treating diabetes type 2 by administering ultrarapid acting insulin
Abstract:	Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Inventor(s):	Richardson; Peter (Ringoes, NJ), Baughman; Robert A. (Ridgefield, CT), Potocka; Elizabeth (Bethel, CT), Boss; Anders Hasager (Princeton, NJ), Petrucci; Richard (New Canaan, CT)
Assignee:	Mannkind Corporation (Valencia, CA)
Application Number:	13/351,855
Patent Claims:	see list of patent claims

Details for Patent 8,623,817

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	June 14, 1996	⤷ Start Trial	2032-01-17
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	August 06, 1998	⤷ Start Trial	2032-01-17
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	September 06, 2007	⤷ Start Trial	2032-01-17
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	June 06, 2017	⤷ Start Trial	2032-01-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,623,817

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2010021879	⤷ Start Trial
United States of America	9943571	⤷ Start Trial
United States of America	9597374	⤷ Start Trial
United States of America	8258095	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.